Connect Biopharma Holdings (CNTB) Price to Sales (2024 - 2026)

Connect Biopharma Holdings has disclosed Price to Sales across 3 years of filings, most recently posting 54.15 for Q2 2026.

• In Q2 2026, Price to Sales fell 95.23% year-over-year to 54.15; the TTM figure through Jun 2026 stood at 50.75 (up 83.1% YoY), while the FY2025 annual figure was 2486.99, up 84663.57% from the prior year.
• Price to Sales came in at 54.15 for Q2 2026 at Connect Biopharma Holdings, down from 972.22 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 5264.8 in Q3 2025 to a low of 54.15 in Q2 2026.
• Average Price to Sales over 3 years is 1266.77, with a median of 540.82 recorded in 2026.
• Year-over-year, Price to Sales jumped 7966.03% in 2025 and sank 95.23% in 2026.
• Over 3 years, Price to Sales stood at 109.43 in 2024, then soared by 4711.15% to 5264.8 in 2025, then plunged by 98.97% to 54.15 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 54.15 in Q2 2026, 972.22 in Q1 2026, and 5264.8 in Q3 2025.